World Library  
Flag as Inappropriate
Email this Article

Tedatioxetine

Article Id: WHEBN0026482400
Reproduction Date:

Title: Tedatioxetine  
Author: World Heritage Encyclopedia
Language: English
Subject: Serotonin–norepinephrine–dopamine reuptake inhibitor, Vortioxetine, D-161, Sercloremine, Monoaminergic
Collection: Antidepressants, Piperidines, Thioethers
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Tedatioxetine

Tedatioxetine
Systematic (IUPAC) name
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
Clinical data
Legal status
  • Investigational
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  YesY
KEGG  N
Synonyms Lu AA24530; Lu-AA-24530
Chemical data
Formula C18H21NS 
Mol. mass 283.43 g/mol
 N   

Tedatioxetine (Lu AA24530) is an antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD).[1][2] Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and in addition as a 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.[3][4][5][6][7] It is currently in phase II clinical trials.[1]

See also

References

  1. ^ a b "Pipeline of Lundbeck". Retrieved 25 August 2013. 
  2. ^ "Search of: Lu AA24530 - List Results - ClinicalTrials.gov". 
  3. ^ "Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression". Retrieved 7 April 2014. 
  4. ^ Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206.  
  5. ^ Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105.  
  6. ^ "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech". 
  7. ^ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". 

External links

  • Lu AA24530 shows positive results in major depressive disorder phase II study



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.